FO
RVNC

FT Options’s Revance Therapeutics, Inc. RVNC Stock Holding History

FT Options’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,577
Closed -$157K – 458
2016
Q2 		$157K Buy
+11,577
New +$205K 0.13% 119

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FT Options's RVNC Position: Q3 2016 in Review

FT Options sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2016, closing a stake of 11,577 shares — an estimated $157K sold.

FT Options first reported a position in RVNC in Q2 2016 and held it in 1 quarter. The position peaked at $157K in Q2 2016. 74 funds tracked by Wall St. Rank hold RVNC as of Q3 2016.

  • FT Options reported no remaining Revance Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • FT Options sold 11,577 Revance Therapeutics, Inc. shares in Q3 2016, an estimated $157K.
  • FT Options first reported a position in Revance Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • FT Options's Revance Therapeutics, Inc. position peaked at $157K in Q2 2016.
  • 74 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2016.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.